Expert BioTech & Life Sciences Accountants

From navigating complex grant funding to structuring pre-revenue valuations, we help you reach clinical milestones and commercialisation.

Talk to our experts

Why Pre-Revenue BioTech Startups Need Specialist Accountants

Standard accounting doesn’t work when your product takes years and millions to reach the market.

We know that in the life sciences sector, traditional financial modelling goes out the window. You need expert BioTech accountants who understand the mechanics of pre-revenue growth and the regulatory hurdles you face.

Funding the Long Haul: Our life sciences accounting team helps you map and manage the extended cash runways required to get through preclinical phases and Phase I/II trials, ensuring you don’t hit a financial wall before your science can prove itself.

Maximising Non-Dilutive Capital: BioTech relies heavily on specialised funding. Our extensive experience as BioTech accountants makes us experts at navigating the intricate reporting requirements of Innovate UK, Horizon Europe, and other major grant bodies so you stay compliant and funded.

Valuing the Intangible: Before you have revenue, your value lies in your IP and data. We help you accurately track, capitalise, and present your research and development costs to maximise valuation during early funding rounds.

Fractional CFO & Accounting Services for Life Sciences

Milestone-Driven Fractional CFO: Consider us your commercial co-founders. Our fractional CFOs for BioTech build complex, scenario-based financial models tied directly to your scientific milestones, ensuring your board packs clearly translate clinical progress into financial value.

Specialist R&D Tax & Grant Audits: Your biggest financial lever is your research spend. We ensure you are claiming every eligible penny of R&D tax relief while providing the specialised grant audits required by major funding institutions.

Investor-Ready Audit & Tax: BioTech cap tables can get complicated quickly with multiple tranches, EIS/SEIS requirements, and institutional investors. We provide heavyweight audit and tax structuring that stands up to the strictest due diligence.

Licensing & M&A Readiness: Whether you are structuring a lucrative out-licensing agreement with a major pharma player or preparing the data room for a full acquisition, we help benchmark your valuation and structure the deal to protect founder equity.

Data-Driven Insights for Scientific Founders

We don’t just observe the life sciences sector; we actively track its financial pulse. Our deep integration within the deep-tech and biotech venture space means we know exactly how investors are currently pricing early-stage science.

Here is some of our latest research into the BioTech Market.

More Insights →

Startup Agility Meets Top 100 Muscle

As RouseFinerva, we bring you the best of both worlds. You get the agile, milestone-focused advisory and fractional CFO expertise of Finerva, backed entirely by the century-long, Top 100 audit and tax infrastructure of Rouse Partners. We are built to support you from your first seed round in the lab all the way to a global pharma buyout, without you ever needing to change firms.

Ready to scale your BioTech business with confidence?

Let’s talk about your clinical milestones, your runway, and your next funding round.

Speak to our BioTech Expert

020 3422 9800
  • Adam Brodie Co-Founder

    Adam leads the fractional CFO team which has significant experience of capital raising, scaling, M&A and successful exits. Previously, he was a CFO and led the successful Exit to NYSE-listed Solera Holdings.

Let's set up a meeting to discuss your growth goals and growing pains.




    By submitting this form I give permission for Finerva to contact me. Privacy Policy.

    • - Dave Cook - Mason & Cook

      “Apart from being extremely experienced and knowledgeable in M&A transactions Finerva were very patient and always used language I understood. They gave me confidence and security and I knew they were working for my best interests.”

    • - Antony Tikhonov - Seedrs

      “Finerva team are always fast to pick up conversations with the entrepreneurs and understand their needs. Many of them leave us very positive feedback after cooperation with Adam and his team.”

    • - Julian Swan - PlasmaTrack

      ”We were very happy with the support we received in our early stages of setting the business up. Specifically the creation of a financial model which formed part of our Angel Investment pitching.”

    • - Philip Barnes - Auxita

      ”Knowledge and responsiveness are the two words that I tell people most who ask me about Finerva. Operating a company from Australia with Finerva helping in the UK, gives me confidence.”

    • - Steve Cleverley - Oxentia

      ”I’ve always been impressed by the knowledge, professionalism, & level of service provided by Finerva. Thoroughly recommended for any SME’s financial support.”

    • - Helen Jackson - GripAble

      “Finerva are a great resource – the whole team have been, and continue to be, supportive in all circumstances across the broad spectrum of financial services. I feel that I can always pick up the phone and get a response on a timely basis and a reasonable price. You have also been extremely patient given the intense nature of our growth stage!”

    • Complete technology group logo - Mark Burrows - Complete Technology Group

      ”Finerva are an excellent partner both for start ups and more mature organisations. Their ability to work with you and help with the challenges you meet as you scale indicates a real partnership approach.”

    • - Nicola Koronka - Missive

      We’ve switched from a top 10 firm to Finerva and have immediately felt the difference. The team understand small business finance and offer strategic yet practical counsel.”

    • - James Ballard - Soar Running

      “Finerva have assisted us on multiple investment rounds. On every occasion the financial models we have built have stood up to the test after many professional investors scrutinised them.”

    • - Gary McKay – APPII

      “Knowing that Finerva understand the pressures of starting a new business is very reassuring.”

    • - Chris Ward – Klive Agency

      “Finerva are very much a partner to Klive and not a supplier. If you are a start up, time starved, focused on building client and customer relationships then trust them to manage your bookkeeping and tax affairs with diligence, accuracy and passion.”

    • - Riya Pabari – Founders Academy

      “Finerva is a fantastic source of insight and strategic counsel over the EIS/SEIS fundraising process – always responsive, clear and thoughtful.”

    • - Haydn Brooks – Risk Ledger

      “R&D Tax Credits – an easy service and good price. Ben put up with my constant questioning and poor writing skills so highly recommended!”

    • - Phil Barry – Blokur

      “Finerva provided excellent advice on structure for our EMI share option scheme, especially when negotiating a fair tax valuation with HMRC.”

    • - James Hadley - Immersive Labs

      “Thank you! You and the team were great for our initial lift off and it has been an amazing experience!”

    • - Sally Smith - My Clinical Outcomes

      “Finerva drove and delivered a highly efficient R&D process from start to finish with a quick turnaround time to receipt of HMRC repayment.”

    • - James Beddows - RIDEto

      “Finerva do things differently – at one of their investor evenings we found an investor who is also a former FTSE100 Executive.”

    • - Gretchen Lennon - Lennon Legal

      ”Finerva is my go-to recommendation for clients looking for advice on EIS matters. They combine top-quality technical knowledge with a commercial, practical approach.”

    • - Bill Cogan - Seven Legal

      “Our clients are consistently impressed with Finerva’s expertise, responsiveness and commercial approach to the more complex EIS support required by fast growth clients.”

    • - Sam Bartholomew - All Mountain Rental

      “The team at Finerva helped with valuable advice regarding a nascent, but relatively complex M&A deal. They understood the pertinent issues quickly and were able to offer valuable perspective from other industries to help us define and refine our understanding of the economics of the trade. Highly recommended.”

    < >